Invitrogen’s Predictor hERG fluorescence polarization assay kit is said to be the first commercially available non-radioactive, homogenous assay kit for high-throughput screening of compounds interacting with the hERG ion channel.
According to the company, the Predictor hERG assay eliminates radioactivity and allows researchers to rapidly and accurately triage compounds for more detailed patch-clamp analysis. In addition, the Predictor hERG assay results are predictive of patch-clamp data, faster and less expensive than current radioligand displacement tests.
Brian Pollok, chief scientific officer of Invitrogen, said: “The Predictor hERG assay delivers a novel solution that is accurate, efficient and convenient for determining potential hERG liability of compounds.”